Advertisement

Incorporating non-biological factors into the TNM staging system for better prognostication and decision-making in testicular cancer

  • Yongqiang Huang
  • Haoyue Sheng
  • Junyu Zhang
  • Qi Liu
  • Dingwei YeEmail author
  • Guohai ShiEmail author
Original Article
  • 52 Downloads

Abstract

Background

We combined county-level socioeconomic status (SES), marital status and insurance status to introduce NBF-stage, which were further incorporated into the American Joint Committee on Cancer (AJCC) TNM staging system to generate an integrated staging system for better prognostication and decision-making for testicular cancer patients.

Methods

15,324 eligible patients diagnosed with primary testicular cancer between January 1, 2007 and December 31, 2015 were strictly selected from the Surveillance, Epidemiology, and End Results (SEER) database. Independent survival predictors were determined based on Cox proportional hazards model. The Kaplan–Meier survival curves were conducted to describe the difference in predicting survival probability and the Multivariate Cox proportion hazard regression analyses were established to compare the cancer-specific survival (CSS) and overall survival (OS) difference among NBF stages or NBF–TNM subgroups.

Results

County-level SES, marital status and insurance status were independent prognostic non-biological factors (NBFs) in our study (P < 0.05). NBF-stage (combination of SES, marital status, and insurance status) was also an independent survival predictor in TC (P < 0.05). NBF1 patients had 167% increased risk of cancer-specific mortality (CSM) as compared to NBF0 patients in testicular cancer (P < 0.01). And NBF0 patients all had a better CSS as compared to NBF1 patients of the same TNM stage both in seminoma and non-seminomatous germ cell tumor (P < 0.05).

Conclusions

Incorporation of NBFs into AJCC TNM staging system in testicular cancer would potentially impact treatment decisions where treatments would not be rendered for a typically curable cancer with multi-modal therapy.

Keywords

Non-biological factors AJCC TNM stage SEER Testicular cancer, stage I 

Abbreviations

NBF

Non-biological factor

TC

Testicular cancer

TGCT

Testicular germ cell tumor

AJCC

American Joint Committee on Cancer

IGCCCG

International Germ Cell Cancer Collaborative Group

TNM

Tumor, Node, Metastasis

SES

Socioeconomic status

SEER

Surveillance, Epidemiology, and End Results

CSS

Cancer-specific survival

CSM

Cancer-specific mortality

hCG

Human chorionic gonadotrophin

AFP

Alpha-fetoprotein

SGCT

Seminomatous germ cell tumor

NSGCT

Non-seminomatous germ cell tumor

CI

Confidence interval

SGCT

Seminomatous germ cell tumor

NSGCT

Non-seminomatous germ cell tumors

Notes

Acknowledgements

We thank the Surveillance, epidemiology, and End Results (SEER) program for providing their platforms and contributors for their valuable datasets. This study was funded by the National Natural Science Foundation of China (Grant No. NSFC 81672512).

Author contributions

GS and DY had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: YH, GS. Acquisition of data: HS. Analysis and interpretation of data: JZ, QL. Drafting of the manuscript: YH, QL. Critical revision of the manuscript for important intellectual content: Statistical analysis: YH, HS, QL. Obtaining funding: DY, GS. Administrative, technical, or material support: DY, GS. Supervision: DY, GS. Other (specify): None.

Compliance with ethical standards

Conflict of interest

This paper does not contain any studies with human participants or animals. Informed consent was not needed because the present study based on a publicly available database without identifying patient information. The author has no relevant affiliations or financial conflict with the subject matter or materials discussed in the manuscript. Peer reviewers on this article have no special financial or relationships to declare.

Supplementary material

345_2018_2603_MOESM1_ESM.docx (14 kb)
Supplementary material 1 (DOCX 13 kb)
345_2018_2603_MOESM2_ESM.docx (13 kb)
Supplementary material 2 (DOCX 13 kb)

References

  1. 1.
    Cancer Stat Facts: Testicular Cancer. SEER. https://seer.cancer.gov/statfacts/html/testis.html. Accessed 19 Dec 2017
  2. 2.
    La Vecchia C et al (2010) Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol 21(6):1323–1360CrossRefGoogle Scholar
  3. 3.
    Hoffmann R et al (2014) Innovations in health care and mortality trends from five cancers in seven European countries between 1970 and 2005. Int J Pub Health 59(2):341–350CrossRefGoogle Scholar
  4. 4.
    Fizazi K et al (2004) Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 22(19):3868–3876CrossRefGoogle Scholar
  5. 5.
    Lobo J et al (2018) Testicular germ cell tumors: revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists. Hum Pathol 82:113–124CrossRefGoogle Scholar
  6. 6.
    Osbun N et al (2017) Characteristics of patients with sertoli and leydig cell testis neoplasms from a national population-based registry. Clin Genitourin Cancer 15(2):e263–e266CrossRefGoogle Scholar
  7. 7.
    Boormans JL et al (2017) Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage i seminoma testis patients under surveillance: a systematic review by the testicular cancer guidelines panel. Eur Urol.  https://doi.org/10.1016/j.eururo.2017.09.025 CrossRefPubMedGoogle Scholar
  8. 8.
    Kamel MH et al (2016) Insurance status and differences in treatment and survival of testicular cancer patients. Urology 87:140–145CrossRefGoogle Scholar
  9. 9.
    Markt SC et al (2016) Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. Cancer 122(20):3127–3135CrossRefGoogle Scholar
  10. 10.
    Fossa SD et al (2011) Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. J Clin Oncol 29(8):963–970CrossRefGoogle Scholar
  11. 11.
    Oldenburg J et al (2015) Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol 26(5):833–838CrossRefGoogle Scholar
  12. 12.
    Mead GM, Stenning SP (1997) The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol (R Coll Radiol) 9(4):207–209CrossRefGoogle Scholar
  13. 13.
    Cheng L et al (2018) Testicular cancer. Nat Rev Dis Primers 4(1):29CrossRefGoogle Scholar
  14. 14.
    Abdel-Rahman O (2018) Incorporating age into International Germ Cell Consensus Classification (IGCCC): a time to move forward? Expert Rev Anticancer Ther 18(1):101–105CrossRefGoogle Scholar
  15. 15.
    Sun M et al (2011) Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: a survival analysis. Cancer 117(18):4277–4285CrossRefGoogle Scholar
  16. 16.
    Robert SA et al (2004) Socioeconomic risk factors for breast cancer: distinguishing individual- and community-level effects. Epidemiology 15(4):442–450CrossRefGoogle Scholar
  17. 17.
    Du XL et al (2006) Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer 106(6):1276–1285CrossRefGoogle Scholar
  18. 18.
    Rosen A et al (2011) Global trends in testicular cancer incidence and mortality. Eur Urol 60(2):374–379CrossRefGoogle Scholar
  19. 19.
    EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1Google Scholar
  20. 20.
    Abern MR, Dude AM, Coogan CL (2012) Marital status independently predicts testis cancer survival–an analysis of the SEER database. Urol Oncol 30(4):487–493CrossRefGoogle Scholar
  21. 21.
    DiMatteo MR (2004) Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol 23(2):207–218CrossRefGoogle Scholar
  22. 22.
    Boyle P (2004) Testicular cancer: the challenge for cancer control. Lancet Oncol 5(1):56–61CrossRefGoogle Scholar
  23. 23.
    Richie JP (2003) Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Urol 170(3):1041CrossRefGoogle Scholar
  24. 24.
    Aparicio J et al (2014) Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol 25(11):2173–2178CrossRefGoogle Scholar
  25. 25.
    Aparicio J et al (2011) Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol 29(35):4677–4681CrossRefGoogle Scholar
  26. 26.
    Chevreau C et al (2004) Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 46(2):209–214 (discussion 214–5) CrossRefGoogle Scholar
  27. 27.
    Tandstad T et al (2009) Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 27(13):2122–2128CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of UrologyFudan University Shanghai Cancer CenterShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  3. 3.Department of Colorectal SurgeryFudan University Shanghai Cancer CenterShanghaiChina

Personalised recommendations